It includes tracking down key people from the industry and interviewing them to validate the data. Numbers extracted from secondary research have been authenticated by conducting proper primary research. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. The team collects facts and data related to the market from different geography to provide a better regional outlook. Different approaches have been worked on to derive the market value and market growth rate. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. The market study of the US dPCR and qPCR market is incorporated by extensive primary and secondary research conducted by the research team. Thus, the introduction of such products enhanced the company's growth and revenue generation. The company expanded the instruments portfolio for the molecular diagnostics segment with the invention of the AriaDx Real-Time PCR System, for in-vitro diagnostic use. expanded its product portfolio and introduced a real-time PCR system for clinical diagnostics. For instance, in July 2017, Agilent Technologies Inc. These key companies are actively adopting various strategies such as new product launches and approvals, merger and acquisition, partnerships and collaborations, and many others in order to thrive in a competitive environment. The market growth in the country is also attributed to the presence of large players, such as Abbott Laboratories, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., and many others in the country. The significant government sending for R&D in healthcare is promoting the R&D of such advanced technology across the country thereby promoting the growth of the dPCR and qPCR market during the forecast period. According to the Personalized Medicine Coalition, biopharmaceutical researchers predict a 69% increase in the number of personalized medicines in the development over the next five years. announced to award a grant of $10,000 to the labs that are working with real-time PCR reagents. In 2015, the federal agencies had invested almost a total of $35.9 billion in R&D, with the National Institutes of Health (NIH) that comprises $29.6 billion of share. There has been an increase in the US healthcare R&D investment since 2013 till 2015. According to the Research America organization, the US had spent almost $158.7 billion in the R&D of medical and healthcare sector in 2015. The major aspects that contribute to its high market share include the fact that the country emphasizes more towards increasing the treatment efficiency of diseases such as cancer, generating forensic DNA profiles from samples of DNA and processing DNA for sequencing. The US is anticipated to hold considerable market share in the global dPCR and qPCR market. The US digital PCR (dPCR) and real-time PCR (qPCR) market is expected to grow at a CAGR of 8.1% during the forecast period. US Digital PCR (dPCR) and Real-Time PCR (qPCR) Market Size, Share & Trends Analysis Report, by Technology (Quantitative PCR and Digital PCR), by Product (Reagents and Consumables, Instruments, and Software), by Application (Research Application, Clinical Application, and Forensic Application) and Forecast, 2019-2025.
0 kommentar(er)
